- Cancer research
- Career spotlights
- Customer stories
- Gene editing
- Single cell analysis
- Stem cell research
- Tips and troubleshooting
- ICYMI: 2018 blog posts
- About our blog
Unlocking cardiomyocyte heterogeneity: the role of transcription factors
Meeting the challenges of heart disease with stem cell research
Cardiovascular disease has a significant impact on global health and the world economy (Benjamin et al. 2017). For example, heart failures such as strokes or infarcts can cause irreversible damage to cardiac tissue and are potentially deadly medical emergencies. Therefore, researchers are working to characterize cardiomyocytes (which are involved in the restoration of cardiac tissue) as part of the ongoing effort to develop tools for treating heart disease. We discussed some of the methods and challenges of cardiomyocyte research with Jared Churko, PhD, who is currently the Director of the iPSC Core and an Assistant Professor in the Department of Cellular and Molecular Medicine at the University of Arizona. His lab is studying the mechanisms of heart disease by utilizing human induced pluripotent stem cells (hiPSC) to generate cardiac cell types.
In a recent article, Jared Churko and colleagues studied the hiPSC-cardiomyocyte transcriptome and identified different cardiomyocyte subpopulations based on RNA-seq single-cell analysis (Churko et al. 2018). To better understand these subpopulations, the authors knocked out transcriptional regulators using CRISPR technology and identified three transcription factors involved in hiPSC-cardiomyocyte differentiation. These transcription factors could potentially be used to enrich for cardiomyocytes in specific developmental stages with the desired functional characteristics needed to treat various cardiac diseases.
Dr. Churko visited Takara Bio recently and we sat down with him to talk about his research, as well as the benefits and limitations of single-cell RNA-seq as applied to hiPSC-derived stem cell analysis. Here are some excepts from our conversation.
Can you describe your project?
My research focuses on how heart cells—the cells that keep your heart beating—are different from each other and how we can generate them in culture. In the future, we hope to use these new heart cells to heal damaged hearts in people who have an underlying heart condition.
There are different types of specialized heart cells. How does your research show what’s happening in the model system you are using?
Certain diseases only affect certain varieties of heart cells, so it’s important to be able to make different types of heart cells. For example, if you have an infarct or ischemia in your ventricular cells, you want to make sure you use ventricular cells to repair the resulting damage. This is important because if you add an electrical-type cell like a nodal cell instead, you will cause irregular beating in the ventricular region of the heart. My research is focused on making sure we’re engineering new heart cells that are properly tuned for the area of the heart where the disease is occurring, so that in the future they can be used to attempt to cure the disease.
Why is single-cell RNA seq important for your work?
It’s due to the resolution that you get. Although you get a lot of data from bulk sequencing, single-cell RNA seq allows you to distinguish between different subtypes and to look at different transcripts at a single-cell level, versus compiling all your data using a bulk RNA-seq method. With a single-cell method, a single population of cells that you are interested in can be isolated and analyzed, keeping other cell populations for different projects or different kinds of studies. This is of major importance, because if a certain cancer cell occurs at a frequency of 0.001% in a population of cells, that wouldn't be detected using bulk sequencing. But if single-cell sequencing is performed on that particular cell, its specific gene expression profile can be analyzed and targeted therapeutics can be developed, versus getting more noise from the other cells that you’ve also sequenced using bulk methods.
What are the limitations of the technologies used in your work?
The biggest limitation is adding understanding to the data—being able to say what it means. For example, "What's important?", "What genes are important?", and "What are you using as your reference?" The biggest concern is not whether we can get the data now, but actually acquiring enough background knowledge to make sense of it, so we can use it downstream.
We are excited to learn how innovative methods are applied to generate advances in research. Jared's research confirmed CRISPR knockouts of the transcription factors with PCR using our PrimeSTAR GXL DNA Polymerase followed by Sanger sequencing. The library used for single-cell RNA-seq analysis was generated with our SMARTer Ultra Low RNA Kit for the Fluidigm C1. We are inspired to see how he used cutting-edge tools to find solutions to his research problems.
Benjamin, E. J. et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation 135, e146–e603 (2017).
Churko, J. M. et al. Defining human cardiac transcription factor hierarchies using integrated single-cell heterogeneity analysis. Nat. Commun. 9, 4906 (2018).
Back to Blog Front
- Big problems from small bugs
- Using the power of RNA-seq to characterize brain cell types
- Choosing a his-tagged purification resin
- When your his-tagged constructs don't bind
- Taking the SMARTer approach to RNA-seq of FFPE tissues
- Advancing cancer research with plasma-seq
- Efficient nonviral T-cell engineering: CRISPR takes a giant step towards the clinic
- Amplifying our understanding of breast cancer metastases
- How to choose the right tools for iPSC-derived disease model development
- Cardiac transcription heirarchies
- ICYMI: 2018 blog posts
- Bringing epigenomic profiling to the single-cell biology stage
- Accelerating chromatin mapping with single-cell ATAC-seq
- Top 5 considerations when automating single-cell sequencing
- What's inside automated single-cell RNA-seq platforms?
- Women in science at TBUSA
- Career spotlight: technical writer
- Career spotlight: field applications scientist
- Career spotlight: technical support scientist
- Career spotlight: associate director of R&D
- 5 tips to make your single-cell RNA-seq experiments a success
- Maximize transduction efficiency in hematopoietic cells
- Cancer immunotherapy
- Customer spotlight: profiling transcription factors with CUT&RUN sequencing
- Web and mobile apps
- Successful knockout experiments part I
- Successful knockout experiments part II
- Using UMTs in NGS experiments
- One-step vs. two-step RT-qPCR
- Avoiding DNA contamination in PCR
- Choosing a CMO partner for stem cell therapy manufacturing
- 20 years of human stem cell research
- Better biobanking with high-throughput qPCR
- Accurate detection of SNVs and CNVs in a single, low-pass sequencing run
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.